Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus sintilimab as second-line therapy for advanced biliary tract tumors
ChiCTR1900022003Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib and sintilimab in biliary cancer, gallbladder cancer and cholangiocarcinoma (CCA), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Overall survival. Started Jul 2019; status: recruiting.
02
Drugs
anlotinibsintilimab
03
Conditions
biliary cancergallbladder cancercholangiocarcinoma (CCA)
Beyond the preview
Go deeper on ChiCTR1900022003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022003.